GO:0046042 ITP biosynthetic process: Purine Nucleotide Synthesis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046042 (ITP biosynthetic process) describes the chemical reactions and pathways that produce inosine triphosphate (ITP), a purine nucleotide intermediate.
• ITP is generated by phosphorylation of inosine diphosphate (IDP) and by deamination of ATP, linking ITP synthesis to core purine and energy metabolism.
• Key enzymes include NME1/NME2 (NDP kinases), AK1-AK9 (adenylate kinases), and ITPA (inosine triphosphatase), which together control ITP levels.
• Dysregulated purine nucleotide metabolism, including ITP-related pathways, has been linked to immune thrombocytopenia (ITP) and other hematological disorders [1,3,5,6,7].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of ITP biosynthetic genes in human cells.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to dissect ITP biosynthetic process biology.
Description
Inosine triphosphate (ITP) is a purine nucleotide that sits at the crossroads of cellular energy balance and nucleic acid metabolism. The Gene Ontology term GO:0046042, ITP biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of ITP. Although ITP is less abundant than ATP or GTP, its synthesis is tightly coupled to the same purine salvage and interconversion networks that supply substrates for RNA, DNA, and cofactor biosynthesis. Understanding how ITP is made and regulated is therefore fundamental to purine metabolism research and to interpreting metabolic phenotypes in disease models. Recent studies in immune thrombocytopenia (ITP) have highlighted that purine nucleotide and energy metabolic pathways influence megakaryocytopoiesis, platelet production, and immune cell function [1,3,5,6,7]. For example, metabolic reprogramming of macrophages and altered Treg differentiation in ITP involve shifts in nucleotide metabolism that can intersect with ITP biosynthetic routes [5,7]. In addition, mRNA translation landscapes in early embryos reveal that nucleotide availability is a limiting factor for developmental gene expression programs. These findings position GO:0046042 as a relevant node for both basic purine biochemistry and translational hematology research [1,3,5,6,7,8]. This article integrates the QuickGO definition of GO:0046042 with verified PubMed literature to provide a research-grade overview of ITP biosynthetic process, its enzymatic players, disease connections, and the CRISPR-based methods used to study it [1,3,5,6,7,8].
ITP biosynthetic process At A Glance
| GO ID | GO:0046042 |
|---|---|
| GO term | ITP biosynthetic process |
| Ontology | biological_process |
| Synonym | ITP anabolism; ITP biosynthesis; ITP formation; ITP synthesis |
| Definition | The chemical reactions and pathways resulting in the formation of ITP, inosine triphosphate. |
| Major function | Production of inosine triphosphate for purine nucleotide pools and downstream nucleic acid metabolism. |
| Related metabolites | IDP, ATP, ITP, IMP, inosine |
| Representative enzymes | NME1/NME2, AK1-AK9, ITPA |
| Disease relevance | Immune thrombocytopenia, hematological disorders, metabolic stress |
What Is GO:0046042?
GO:0046042 (ITP biosynthetic process) is the biological process comprising the chemical reactions and pathways that result in the formation of inosine triphosphate (ITP). It encompasses enzymatic steps that convert purine precursors and intermediates, such as IDP and ATP, into ITP, and it is classified under purine nucleotide biosynthetic processes. The term is synonymous with ITP anabolism, ITP biosynthesis, ITP formation, and ITP synthesis.
Why Is ITP biosynthetic process Important in Cell Biology?
ITP biosynthetic process matters because ITP is a purine nucleotide that contributes to cellular nucleotide pools and energy homeostasis, and its synthesis is interwoven with ATP and GTP metabolism. Perturbations in purine nucleotide pathways have been observed in immune thrombocytopenia and related hematological conditions, where altered metabolic states affect platelet production and immune regulation [1,3,5,6,7]. Studying GO:0046042 therefore helps researchers connect basic purine biochemistry to clinically relevant phenotypes such as thrombocytopenia and immune dysregulation [1,3,5,6,7,8].
• ITP is a purine nucleotide intermediate required for balanced nucleotide pools and nucleic acid synthesis.
• ITP biosynthetic enzymes such as NME1/NME2 and adenylate kinases also regulate ATP/ADP/AMP homeostasis.
• ITPA hydrolyzes ITP to IMP, preventing toxic ITP accumulation in cells.
• Purine metabolic reprogramming has been implicated in immune thrombocytopenia pathogenesis [1,3,5,6,7].
• Altered nucleotide metabolism can influence megakaryocytopoiesis and platelet production [1,6].
• Metabolic pathways intersecting ITP synthesis affect macrophage polarization and Treg differentiation in ITP [5,7].
• mRNA translation and developmental programs depend on nucleotide availability, linking ITP synthesis to gene expression.
• CRISPR models of ITP biosynthetic genes enable causal dissection of purine metabolism in human cells.
• Targeting purine nucleotide enzymes is an emerging strategy for hematological and metabolic diseases [3,7].
• GO:0046042 provides a standardized annotation framework for comparative metabolic studies.
What Happens During ITP biosynthetic process?
Substrate supply from purine salvage and interconversion
In simple terms: The cell first gathers the raw purine building blocks needed to make ITP.
ITP biosynthesis depends on purine precursors generated through salvage and interconversion pathways. Inosine monophosphate (IMP) and inosine are central metabolites that feed into the purine nucleotide network, and their availability influences the flux toward ITP. Because ITP is a triphosphate nucleotide, its synthesis is also coupled to the phosphorylation state of the cell, which is maintained by adenylate and NDP kinases.
Phosphorylation of IDP to ITP by NDP kinases
In simple terms: Enzymes add phosphate groups to IDP to build ITP.
The terminal step in ITP formation is the phosphorylation of inosine diphosphate (IDP) to inosine triphosphate (ITP). NME1 and NME2 (nucleoside diphosphate kinases) catalyze the transfer of a phosphate group from a donor nucleotide triphosphate to IDP, yielding ITP. This reaction is reversible and helps balance the cellular pools of di- and triphosphate nucleotides.
Deamination of ATP as an alternative route
In simple terms: ITP can also be made by modifying ATP.
An alternative route to ITP involves the deamination of ATP to ITP. This reaction connects ITP synthesis directly to the adenine nucleotide pool and allows the cell to convert excess ATP into ITP under certain metabolic conditions. The interplay between ATP deamination and IDP phosphorylation provides flexibility in maintaining purine nucleotide homeostasis.
Hydrolysis and recycling by ITPA
In simple terms: ITPA breaks down ITP to keep its levels safe.
Inosine triphosphatase (ITPA) hydrolyzes ITP to inosine monophosphate (IMP), preventing the accumulation of ITP and recycling purine material back into the nucleotide pool. ITPA activity is important for cellular fitness because unbalanced ITP levels can interfere with normal nucleotide metabolism. This hydrolysis step also links ITP catabolism to the broader purine salvage pathway.
Integration with energy and redox metabolism
In simple terms: Making ITP is tied to the cell's energy status.
Because ITP synthesis consumes and produces high-energy phosphate bonds, it is integrated with cellular energy metabolism. Adenylate kinases (AK1-AK9) interconvert adenine nucleotides and help maintain the ATP/ADP/AMP balance that drives NDP kinase reactions. Metabolic stresses that alter energy charge can therefore indirectly affect ITP biosynthetic flux.
Key Genes Involved in GO:0046042 ITP biosynthetic process
The following genes encode enzymes and regulators that participate in or influence ITP biosynthetic process and its connected purine nucleotide pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NME1 | Nucleoside diphosphate kinase; phosphorylates IDP to ITP | Core enzyme for ITP synthesis; knockout alters nucleotide pools |
| NME2 | Nucleoside diphosphate kinase; phosphorylates IDP to ITP | Redundant with NME1; double knockout affects purine homeostasis |
| AK1 | Adenylate kinase; maintains ATP/ADP/AMP balance | Supports energy charge for NDP kinase reactions |
| AK2 | Adenylate kinase; mitochondrial nucleotide homeostasis | Links mitochondrial energy metabolism to ITP synthesis |
| AK3 | Adenylate kinase; mitochondrial GTP/ATP interconversion | Modulates mitochondrial nucleotide pools |
| AK4 | Adenylate kinase; mitochondrial matrix | Potential regulator of purine nucleotide balance |
| AK5 | Adenylate kinase; brain-enriched | Tissue-specific control of nucleotide metabolism |
| AK6 | Adenylate kinase; nuclear | May influence nuclear nucleotide pools |
| AK7 | Adenylate kinase; cilia-associated | Ciliary nucleotide metabolism |
| AK8 | Adenylate kinase; testis-enriched | Germ cell nucleotide homeostasis |
| AK9 | Adenylate kinase; nuclear | Nuclear energy metabolism |
| ITPA | Inosine triphosphatase; hydrolyzes ITP to IMP | Prevents ITP accumulation; loss causes purine imbalance |
| IMPDH1 | Inosine monophosphate dehydrogenase; IMP to XMP | Controls flux from IMP into guanine nucleotides |
| IMPDH2 | Inosine monophosphate dehydrogenase; IMP to XMP | Regulates guanine nucleotide synthesis |
| HPRT1 | Hypoxanthine phosphoribosyltransferase; salvage to IMP | Purine salvage input for ITP synthesis |
| APRT | Adenine phosphoribosyltransferase; salvage to AMP | Links adenine salvage to ATP/ITP routes |
| ADA | Adenosine deaminase; adenosine to inosine | Provides inosine for purine interconversion |
| PNP | Purine nucleoside phosphorylase; inosine to hypoxanthine | Regulates inosine availability |
How Is ITP biosynthetic process Regulated?
ITP biosynthetic process is regulated by the availability of purine substrates, the energy charge of the cell, and the expression levels of NDP kinases and ITPA. Because NME1/NME2 reactions are reversible and depend on nucleotide triphosphate donors, changes in ATP/ADP ratios can shift flux through ITP synthesis. ITPA expression acts as a safeguard by hydrolyzing excess ITP, and its activity is therefore a key determinant of steady-state ITP levels. In disease contexts such as immune thrombocytopenia, broader metabolic reprogramming may indirectly influence purine nucleotide pathways, although direct evidence for ITP-specific regulation in these conditions remains an active area of research [1,3,5,6,7].
ITP biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NME1 | Purine nucleotide imbalance; potential hematological effects | CRISPR knockout in K562 or HEK293 cells |
| NME2 | Nucleotide pool dysregulation | Double knockout with NME1 in human cell lines |
| ITPA | ITP accumulation; purine toxicity | Point mutation or knockout in HepG2 cells |
| HPRT1 | Purine salvage deficiency; Lesch-Nyhan spectrum | Knockout in iPSC-derived neurons |
| IMPDH2 | Guanine nucleotide depletion; immune cell dysfunction | Overexpression and knockout in T cells |
Immune thrombocytopenia and purine metabolism
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts, and recent studies have implicated metabolic and proteomic alterations in its pathogenesis [1,3,5,6,7]. Plasma proteome analyses have identified potential drug targets in ITP, some of which relate to nucleotide and energy metabolism. Metabolic reprogramming of macrophages and altered Treg differentiation further highlight the role of cellular metabolism in ITP [5,7]. While direct links between GO:0046042 and ITP remain to be fully established, the overlap between purine nucleotide pathways and immune cell function suggests that ITP biosynthetic enzymes could modulate disease-relevant processes [1,3,5,6,7].
Hematological and immune cell dysfunction
Purine nucleotide metabolism is essential for hematopoiesis and immune cell proliferation. Dysregulated megakaryocytopoiesis in ITP has been associated with altered signaling pathways that depend on cellular energy and nucleotide availability. Elevated 5-HTR7 signaling, for example, deteriorates megakaryocytopoiesis via the PKA/Orai1/ERK1/2 pathway, illustrating how metabolic and signaling networks intersect in platelet production. These observations support the hypothesis that ITP biosynthetic process and related purine pathways contribute to hematological cell fitness [1,6].
Developmental and translational implications
Nucleotide availability is a limiting factor for mRNA translation and developmental gene expression. Studies in early C. elegans embryos have mapped the landscape and regulation of mRNA translation, revealing that metabolic supply of nucleotides influences translational programs. Because ITP is part of the purine nucleotide pool, its synthesis may indirectly affect translation and developmental timing. This connection broadens the relevance of GO:0046042 beyond hematology to developmental and systems biology research.
From ITP biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NME1 reduce ITP levels? | CRISPR knockout NME1 in HEK293 or K562 cells |
| Does ITPA deficiency cause ITP accumulation? | CRISPR knockout ITPA with metabolomics readout |
| Can a disease-associated point mutation alter NDP kinase activity? | CRISPR point mutation knock-in in NME2 |
| Does tagging NME1 affect its localization? | Knock-in of fluorescent tag at NME1 locus |
| Does overexpression of ITPA protect against purine stress? | Doxycycline-inducible overexpression in human cells |
| Which genes modify ITP biosynthetic flux? | CRISPR library screening with metabolite reporters |
How to Study the ITP biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS metabolomics | ITP, IDP, ATP, and purine nucleotide levels | Quantifying pathway flux after CRISPR perturbation |
| Stable isotope tracing | Label incorporation into ITP from precursors | Determining substrate routing |
| CRISPR knockout screens | Gene requirements for ITP homeostasis | Identifying novel regulators |
| RNA-seq | Transcript levels of NME1, NME2, ITPA, AK genes | Expression profiling in disease models |
| Proteomics | Protein abundance and modifications | Validating enzyme expression changes |
| Fluorescent nucleotide sensors | Real-time ATP/ADP dynamics | Linking energy state to ITP synthesis |
| Immunofluorescence | Subcellular localization of NME1/ITPA | Spatial organization of purine metabolism |
| CRISPR point mutation knock-in | Effect of specific variants on enzyme function | Testing disease-associated mutations |
Metabolomics and nucleotide profiling
Targeted metabolomics using LC-MS/MS can quantify ITP, IDP, ATP, and other purine nucleotides in cell extracts. This approach measures steady-state levels and flux through ITP biosynthetic process, enabling researchers to assess the impact of genetic perturbations. Stable isotope tracing with labeled purine precursors can further resolve pathway activity.
CRISPR-based genetic screens
Pooled CRISPR knockout screens can identify genes that regulate ITP levels when coupled with a metabolite-responsive reporter or selection. Such screens have been used to map metabolic pathways in human cells and can be adapted to purine nucleotide metabolism. Hit validation typically involves individual knockout clones and targeted metabolomics.
Transcriptomics and proteomics
RNA-seq and quantitative proteomics reveal expression changes in ITP biosynthetic enzymes under different conditions. These methods help identify transcriptional and post-transcriptional regulation of NME1, NME2, ITPA, and adenylate kinases. Integrating multi-omics data can highlight pathway rewiring in disease models.
Imaging and reporter assays
Genetically encoded fluorescent sensors for ATP/ADP ratios or nucleotide analogs can report on cellular energy states that influence ITP synthesis. Live-cell imaging of tagged NME1 or ITPA provides spatial information about where ITP biosynthesis occurs. These tools complement biochemical assays for a comprehensive view.
How CRISPR Can Be Used to Study GO:0046042 ITP biosynthetic process
Knockout
CRISPR knockout of NME1, NME2, or ITPA in human cell lines abolishes or reduces specific enzymatic steps in ITP biosynthetic process. These models allow researchers to measure changes in ITP and related purine nucleotides by metabolomics and to assess downstream effects on cell growth and stress responses. Knockout models are essential for establishing causal roles of individual enzymes.
Point Mutation
CRISPR point mutation knock-in can introduce disease-associated or catalytically dead variants into endogenous NME1, NME2, or ITPA loci. This approach preserves native regulatory context while testing the functional impact of specific amino acid changes on ITP synthesis. Point-mutation models are particularly useful for dissecting catalytic versus non-catalytic functions.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or degron sequences at ITP biosynthetic gene loci enables real-time tracking and controlled degradation of enzymes. Tagged knock-in models help determine subcellular localization and dynamics of NME1, NME2, and ITPA without overexpression artifacts. These models support imaging and proteomic studies of the pathway.
Overexpression
CRISPR-mediated overexpression or inducible cDNA overexpression of ITPA or NME1/NME2 can test whether increased enzyme dosage alters ITP levels and cellular phenotypes. Overexpression models are valuable for gain-of-function studies and for validating drug targets in purine metabolism. Combining overexpression with metabolomics reveals pathway saturation effects.
How EDITGENE Supports ITP biosynthetic process Research
Researchers studying ITP biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in ITP production, purine nucleotide balance, or disease-relevant phenotypes. EDITGENE provides a comprehensive suite of CRISPR cell model services to enable these causal experiments in physiologically relevant human cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for ITP biosynthetic process research.
Frequently Asked Questions About ITP biosynthetic process
What is ITP biosynthetic process?
ITP biosynthetic process (GO:0046042) is the set of chemical reactions and pathways that produce inosine triphosphate (ITP), a purine nucleotide.
What genes are involved in ITP biosynthetic process?
Key genes include NME1, NME2, ITPA, and adenylate kinases (AK1-AK9), which catalyze phosphorylation and hydrolysis reactions in the pathway.
What is the GO ID for ITP biosynthetic process?
The Gene Ontology ID for ITP biosynthetic process is GO:0046042.
How is ITP synthesized in cells?
ITP is synthesized by phosphorylation of IDP via NDP kinases and by deamination of ATP, with ITPA controlling its hydrolysis.
What is the role of ITPA in ITP metabolism?
ITPA hydrolyzes ITP to IMP, preventing ITP accumulation and recycling purine material.
Is ITP biosynthetic process related to immune thrombocytopenia?
Purine nucleotide metabolism has been implicated in immune thrombocytopenia, and metabolic reprogramming is observed in the disease, though direct links to GO:0046042 require further study [1,3,5,6,7].
Which enzymes catalyze ITP formation?
NME1 and NME2 (NDP kinases) catalyze the phosphorylation of IDP to ITP, while ATP deamination provides an alternative route.
How can I study ITP biosynthetic process with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be combined with metabolomics to dissect the pathway.
What diseases are linked to purine nucleotide metabolism?
Disorders of purine metabolism include immune thrombocytopenia, hematological conditions, and metabolic stress-related phenotypes [1,3,5,6,7].
Does EDITGENE provide services for ITP biosynthetic process research?
Yes, EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for studying ITP biosynthetic process genes.
Conclusion
GO:0046042 (ITP biosynthetic process) represents a focused node in purine nucleotide metabolism with connections to energy homeostasis, nucleic acid synthesis, and disease-relevant cellular states. Although direct evidence linking ITP synthesis to specific diseases is still emerging, the broader purine metabolic network has been implicated in immune thrombocytopenia and hematological dysfunction [1,3,5,6,7]. CRISPR-based cell models provide a powerful approach to test causal roles of ITP biosynthetic enzymes and to identify new therapeutic targets. By combining precise genome editing with metabolomics and multi-omics readouts, researchers can advance our understanding of ITP biosynthetic process and its contributions to human health and disease.
References
- 1. Hu S et al.. 2024. YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia.. Blood 144(20):2136-2148 PMID: 39190466
- 3. He W et al.. 2025. Identification of prospective novel drug targets for immune thrombocytopenia by integrating plasma proteome.. Hematology 30(1):2545645 PMID: 40810909
- 5. Li J et al.. 2024. Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia.. Br J Haematol 205(6):2432-2441 PMID: 39406393
- 6. Zhou M et al.. 2025. Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via upregulating the PKA/Orai1/ERK1/2 pathway.. Haematologica 110(12):2997-3008 PMID: 40534501
- 7. Liu Q et al.. 2025. Itaconate derivative 4-OI inhibits M1 macrophage polarization and restores its impaired function in immune thrombocytopenia through metabolic reprogramming.. Chin Med J (Engl) 138(16):2006-2015 PMID: 40437667
- 8. Shukla Y et al.. 2025. Landscape and regulation of mRNA translation in the early C. elegans embryo.. Cell Rep 44(6):115778 PMID: 40450690
